Physician profile
Scott M Ravis
NPI 1902845720
$5,387.61
in general payments reported to CMS, 2019-2025
30 companies · $2,104 in 2025
The $2,104 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $78.99 · 2022: $137 · 2023: $118 · 2024: $2,950 · 2025: $2,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,765 · Education: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,764.94 |
| Education | $406.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $987.27 | 2023-2025 | |
| Janssen Biotech, INC. | $695.11 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $608.83 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $352.18 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $307.98 | 2024-2025 | Sotyktu |
| Ucb, INC. | $274.71 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $261.00 | 2024-2025 | Taltz, Olumiant, Ebglyss |
| Kerecis Limited | $233.31 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Amgen INC. | $209.92 | 2024-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $163.43 | 2024-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $136.02 | 2024-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $133.08 | 2024 | Vtama |
| Organogenesis INC. | $132.88 | 2024 | Puraply Am |
| Stemline Therapeutics INC. | $124.83 | 2022 | |
| Leo Pharma INC. | $111.12 | 2024-2025 | Adbry |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $91.51 | 2024 | |
| Incyte Corporation | $89.46 | 2024-2025 | Opzelura |
| Pfizer INC. | $85.96 | 2024-2025 | |
| Biowound Solutions, INC. | $65.03 | 2025 | Bio-Connekt |
| Janssen Pharmaceuticals, INC | $52.69 | 2024-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $49.26 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $48.69 | 2024-2025 | Zoryve |
| Takeda Pharmaceuticals U.S.A., INC. | $44.40 | 2025 | Vpriv |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.35 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.33 | 2025 | Cabtreo |
| Verrica Pharmaceuticals INC. | $19.76 | 2024 | Ycanth |
| Organon LLC | $19.29 | 2024-2025 | Vtama |
| Revance Therapeutics, INC. | $16.62 | 2024 | Daxxify |
| Springworks Therapeutics, INC. | $15.80 | 2025 | Gomekli |
| Biofrontera INC. | $12.79 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Ravis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.